This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yates, P. J.
Right arrow Articles by Elston, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yates, P. J.
Right arrow Articles by Elston, R. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2006, p. 1092-1095, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.1092-1095.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro Development of Resistance to Human Immunodeficiency Virus Protease Inhibitor GW640385

P. J. Yates,1* R. Hazen,2 M. St. Clair,2 L. Boone,2 M. Tisdale,1 and R. C. Elston1

GlaxoSmithKline Inc., Stevenage, United Kingdom,1 GlaxoSmithKline Inc., Research Triangle Park, North Carolina2

Received 11 July 2005/ Returned for modification 9 September 2005/ Accepted 30 December 2005

Development of in vitro resistance to GW640385, a new human immunodeficiency virus type 1 protease inhibitor, was studied. Variants characterized included one with <4-fold resistance and amino acid substitutions Q58E/A71V (protease) and P452K (Gag) and one with >50-fold resistance and amino acid substitutions L10F/G16E/E21K/A28S/M46I/F53L/A71V (protease) and L449F/P453T (Gag). The A28S substitution substantially reduced replication capacity.

* Corresponding author. Mailing address: UK Virology, GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom. Phone: 44 1438 763887. Fax: 44 1438 764263. E-mail: pjy29430{at}gsk.com.

Antimicrobial Agents and Chemotherapy, March 2006, p. 1092-1095, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.1092-1095.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hazen, R., Harvey, R., Ferris, R., Craig, C., Yates, P., Griffin, P., Miller, J., Kaldor, I., Ray, J., Samano, V., Furfine, E., Spaltenstein, A., Hale, M., Tung, R., St. Clair, M., Hanlon, M., Boone, L. (2007). In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV. Antimicrob. Agents Chemother. 51: 3147-3154 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»